Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Grazyna
Grazyna Cieplucha, Warszawa PL
| Patent application number | Description | Published |
|---|---|---|
| 20090105483 | PROCESS FOR THE PREPARATION OF PRAMIPEXOLE BASE AND/OR ITS SALTS - The process for the preparation of pramipexole base and/or its pharmaceutically acceptable salts, especially the hydrochloride salt, in the alkylation reaction of (S)-(−)2,6-diamino-4,5,6,7-tetrahydrobenzothiazole with an alkylating agent, wherein the reaction is carried out in the absence of a base, and in a solvent from which the resulting N-monoalkylated product selectively precipitates out as a salt. After isolation from the reaction mixture, the N-monoalkylated product is converted a) into the free pramipexole base upon treatment with an inorganic base and is then converted into another pharmaceutically acceptable pramipexole salt; or b) directly into another pharmaceutically acceptable pramipexole salt or the hydrate thereof. | 04-23-2009 |
Grazyna Cynkowska, Brookline, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090163457 | Compositions and methods for delivering a biologically active agent - The invention relates to codrugs having improved properties, methods for preparing and administering them, and methods of formulating and administering the codrugs as pharmaceutical preparations. In certain embodiments, the codrugs can be locally administered to deliver the constituent biologically active compound in a sustained-release fashion, reducing systemic concentrations of the biologically active compound. | 06-25-2009 |
| 20110183944 | SUSTAINED-RELEASE NSAID/HMG CoA REDUCTASE INHIBITOR COMPOSITIONS - Compositions for controlled release of one or more therapeutic agents where the composition is essentially free of excipients are disclosed. In particular, compositions comprising a HMG-CoA reductase inhibitor, particularly simvastatin, and a NSAID, such as a COX-2 inhibitor, particularly celecoxib, in which greater than 90% of the weight of the composition is made up of the HMG-CoA reductase inhibitor and NSAID are provided. | 07-28-2011 |
Grazyna Formicka-Zeppezauer, Saarbrucken DE
| Patent application number | Description | Published |
|---|---|---|
| 20110034370 | BIS-MET HISTONES - The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a host transformed with said vector, polypeptides encoded by the nucleic acid molecule and pharmaceutical and diagnostic compositions. The present invention also relates to the use of the nucleic acid molecule, vectors, hosts and the polypeptide of the invention for the preparation of a composition for the treatment of diseases. Furthermore, the present invention relates to a method of testing for the presence of the nucleic acid molecule or the polypeptide in a sample and to a kit. | 02-10-2011 |
Grazyna Kmiecik-Lawrynowicz, Fairport, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20110053076 | SUPERCRITICAL FLUID MICROENCAPSULATION OF DYE INTO LATEX FOR IMPROVED EMULSION AGGREGATION TONER - The present disclosure provides methods for incorporating a dye into latex particles via a supercritical fluid microencapsulation technique, in order to achieve improved dispersion of a colorant in the latex and an increase in color gamut. | 03-03-2011 |
| 20110091801 | TONER COMPOSITIONS - The present disclosure provides toners and methods for their production. In embodiments, the amount of coagulant utilized in producing those toners may be less than amounts currently in use, which may have a beneficial effect by reducing the time for coalescence. Modified waxes may also be utilized which provide excellent gloss and charging characteristics. | 04-21-2011 |
| 20110117486 | TONER COMPOSITIONS - The present disclosure provides polyesters suitable for use in forming toners. In embodiments, a polyester may be subjected to phase inversion emulsification, in which charge control agents are added so that the polyester emulsion includes charge control agents therein. The resulting polyester emulsion with charge control agents may then be utilized to form toner particles. | 05-19-2011 |
Grazyna Paliwoda-Probeska, Duisburg DE
| Patent application number | Description | Published |
|---|---|---|
| 20080305341 | Process for Coating Metallic Surfaces With an Anti-Corrosive Coating - A process is disclosed for coating metallic surfaces with an anti-corrosive composition that contains a conductive polymer and is a dispersion that contains the at least one conductive polymer mainly or entirely in particulate form, as well as a binder system. The conductive polymer is at least one polymer based on polyphenylene, polyfuran, polyimidazole, polyphenanthrene, polypyrrole, polythiophene and/or polythiophenylene charged with anti-corrosive mobile anions. Alternatively, the metallic surfaces can be first coated with a dispersion based on conductive polymers in particulate form, then coated with a composition which contains a binder system. | 12-11-2008 |
Grazyna Plucienniczak, Warszawa PL
| Patent application number | Description | Published |
|---|---|---|
| 20100297773 | EXPRESSION CASSETTE, USE OF THE EXPRESSION CASSETTE, VECTOR, HOST CELL, A METHOD FOR PRODUCING A POLYPEPTIDE - The subject matters of invention relate to expression cassette, use of the expression cassette, vector, host cell, a method for producing a polypeptide ensuring its stable expression by the prokaryotic host as well as an use of the expression cassette. The invention enables stable expression of the target polypeptide, in systems where DNA-dependent RNA polymerase recognises promoter regulating synthesis of target protein as well as selection marker, which is required for survival of the host. | 11-25-2010 |
| 20100313298 | EXPRESSION CASSETTE, T-DNA MOLECULE, PLANT EXPRESSION VECTOR, TRANSGENIC PLANT CELL AS WELL AS THEIR USE IN THE MANUFACTURING OF A VACCINE - The described binary vector with containing the expression cassette of the S-HBsAg protein under the control of the constitutive 35S promoter as well as the method of transforming lettuce using a strain of | 12-09-2010 |
| 20110136736 | NEW INSULIN ANALOGUES OF PROLONGED ACTIVITY - New biosynthetic analogues of recombined human insulin of prolonged therapeutical activity, which can find place in prophylactic and treatment of diabetes. | 06-09-2011 |
Grazyna Saganowska, Warszawa PL
| Patent application number | Description | Published |
|---|---|---|
| 20090083059 | SYSTEM AND METHOD FOR RETROACTIVE, DYNAMIC MONITORING OF LOW LAYOUT HEIGHTS IN DANGEROUS EVENTS - The invention relates to a system and to a method for retroactive, dynamic determination and/or monitoring of low layout heights of technical systems ( | 03-26-2009 |
Grazyna Stochel, Krakow PL
| Patent application number | Description | Published |
|---|---|---|
| 20110250143 | PROCESS FOR PREPARING CHLORINS AND THEIR PHARMACEUTICAL USES - The disclosed subject matter includes methods of preparation, properties, pharmaceutical compositions and methods of therapy of sulfonated chlorins and bacterioclorins designed for the photodynamic therapy (PDT) of hyperproliferative tissues such as tumors, hyperproliferative blood vessels and other disorders or abnormalities that are responsive to PDT. In particular, the economical large-scale synthesis of stable chlorins and bacteriochlorins is described. Their properties were tailored to meet those of ideal photosensitizers for PDT. In another embodiment, pharmaceutical compositions and methods of therapy for systemic administration are provided. In a further embodiment, pharmaceutical compositions and methods of therapy for topical administration are also provided. Further provided is a method of labeling a target tissue and providing an image of that tissue by fluorescence of magnetic resonance imaging. | 10-13-2011 |
Grazyna Szymanska, Dedham, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090318357 | Molecules Preferentially Associated with Effector T Cells or Regulatory T Cells and Methods of Their Use - The present invention is based, at least in part, on the finding that certain molecules are preferentially associated with effector T cells or regulatory T cells. Accordingly, immune responses by one or the other subset of cells can be preferentially modulated. The invention pertains, e.g., to methods of modulating (e.g., up- or down-modulating), the balance between the activation of regulatory T cells and effector T cells leading to modulation of immune responses and to compositions useful in modulating those responses. The invention also pertains to methods useful in diagnosing, treating, or preventing conditions that would benefit from modulating effector T cell function relative to regulatory T cell function or from modulating regulatory T cell function relative to effector T cell function in a subject. The subject methods and compositions are especially useful in the diagnosis, treatment or prevention of conditions characterized by a too-vigorous effector T cell response to antigens associated with the condition, in the diagnosis, treatment or prevention of conditions characterized by a weak effector T cell response, in the diagnosis, treatment or prevention of conditions characterized by a too-vigorous regulatory T cell response, or in the diagnosis, treatment, or prevention of conditions characterized by a weak regulatory T cell response. | 12-24-2009 |
| 20110059109 | Methods for inducing or enhancing an immune response by administering GITR-binding antibodies - The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e.g., CD3, are agonistic, and abrogate the suppression of Teff cells by Treg cells. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such binding molecules. Methods of using a binding molecule of the invention to detect human GITR or to modulate human GITR activity, either in vitro or in vivo, are also encompassed by the invention. | 03-10-2011 |
Grazyna Wlodarski, Andover, MN US
| Patent application number | Description | Published |
|---|---|---|
| 20100010476 | Fiber based medical devices and aspiration catheters - Systems for less invasive medical procedures comprise a filter device mounted on an integrated guiding structure and an aspiration catheter. These components can be used together or separately, and the system can be used with other medical devices that are designed for less invasive procedures, such as procedures in a patient's vasculature. The filter device can involve improved torque coupling with a torque coupler associated with a resilient member that correspondingly also provides increased flexibility relative to an overtube that forms a tube for the remaining portions of the device. An actuation tool for the filter device used a systematic loading procedure for proper loading of the corewire and overtube into the actuation tool. A fiber cartridge comprises fibers loaded as a bundle into the cartridge for delivery with the ends of the fibers respectively bonded to radiopaque markers that can be visualized to come together when the filter is properly deployed. The aspiration catheter generally has a rapid exchange format. The catheter can have a radiopaque band that is held in place under metal wire embedded within the polymer forming the tube of the catheter. In some embodiments, the aspiration catheter has a small diameter distal portion that can access into small diameter vessels in which the distal portion has a smaller average diameter than the remaining tube of the catheter. | 01-14-2010 |
| 20110230859 | ASPIRATION CATHETERS FOR THROMBUS REMOVAL - Systems for less invasive medical procedures comprise a filter device mounted on an integrated guiding structure and an aspiration catheter. These components can be used together or separately, and the system can be used with other medical devices that are designed for less invasive procedures, such as procedures in a patient's vasculature. The filter device can involve improved torque coupling with a torque coupler associated with a resilient member that correspondingly also provides increased flexibility relative to an overtube that forms a tube for the remaining portions of the device. An actuation tool for the filter device used a systematic loading procedure for proper loading of the corewire and overtube into the actuation tool. A fiber cartridge comprises fibers loaded as a bundle into the cartridge for delivery with the ends of the fibers respectively bonded to radiopaque markers that can be visualized to come together when the filter is properly deployed. The aspiration catheter generally has a rapid exchange format. The catheter can have a radiopaque band that is held in place under metal wire embedded within the polymer forming the tube of the catheter. In some embodiments, the aspiration catheter has a small diameter distal portion that can access into small diameter vessels in which the distal portion has a smaller average diameter than the remaining tube of the catheter. | 09-22-2011 |
| 20110251629 | EMBOLECTOMY DEVICES AND METHODS FOR TREATMENT OF ACUTE ISCHEMIC STROKE CONDITION - Clot engagement element comprising bundle of unwoven fibers can be assembled to form an acute stroke treatment device. The device has the capability of forming a three dimensional filtration matrix comprising effective pores with a distribution of sizes. The bundle of fiber design allows the device to be effectively delivered into circuitous cerebral arteries to remove clot that causes stroke. The fiber bundle based filtration matrix offers the advantages of conforming to the changing inner perimeter of a blood vessel during a clot removal process and thus the capability to effectively retain and remove a clot in the vessel. The filtration matrix offers the additional advantage to trap any break-off of the clot during the removal process. A plurality of fiber bundles can be combined to form an effective clot engagement element. Supplemental engagement structure as well as mechanical treatment structure can be integrated into the stroke treatment device. The deployment of the fiber based elements can be facilitated by actuation tool. Aspiration can be employed during the clot removal process. | 10-13-2011 |